Skip to main content
. 2022 May 20;6(10):3114–3125. doi: 10.1182/bloodadvances.2022007017

Table 4.

Deterministic sensitivity analysis results

Scenario Fondaparinux vs Argatroban Fondaparinux vs Rivaroxaban Rivaroxaban vs Argatroban
Base case Dominant Trade-off* Trade-off
 Incremental Cost (CHF) −10 653 −11 488 835
 Incremental Effectiveness (AEA) 0.013 −0.084 0.097
 ICER (CHF/AEA) 136 968 8 586
Base case incidence rates − 50% Dominant Trade-off* Dominant
 Incremental Cost (CHF) −7 010 −15 230 −8 219
 Incremental Effectiveness (AEA) 0.007 −0.043 0.050
 ICER (CHF/AEA) 351 595
Base case incidence rates + 50% Dominant Trade-off* Dominant
 Incremental Cost (CHF) −14 144 −7 988 −6 156
 Incremental Effectiveness (AEA) 0.019 −0.122 0.141
 ICER (CHF/AEA) 65 606
Event rates from Al-jabri et al 28 Dominant Rivaroxaban was not assessed in the study
 Incremental Cost (CHF) −18 142
 Incremental Effectiveness (AEA) 0.061
 ICER (CHF/AEA)
Event rates obtained from other published studies (Kang et al. (2015),34 ARTEMIS trial,35 Lewis et al. (2006),36 Hursting et al. (2020),37 Warkentin et al. (2017),19 Linkins et al. (2016),15 MAGELLAN trial38) Trade-off* Dominant Dominated
 Incremental Cost (CHF) −881 −15 963 15 081
 Incremental Effectiveness (AEA) −0.042 0.029 −0.071
 ICER (CHF/AEA) 21 107

Dominant = the first drug (ie, before "vs") costed less and was more effective in preventing adverse events than the comparator.

Dominated = the first drug (ie, before "vs") costed more and was less effective in preventing adverse events than the comparator.

AEA, adverse events averted.

*

Trade-off indicates “less costly but also less effective”; interpretation of cost-effectiveness depends on threshold: costs of averting 1 adverse event

Trade-off indicates “more costly but also more effective”; interpretation of cost-effectiveness depends on threshold: costs of averting 1 adverse event